Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Ramalingam

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

Journal of Thoracic Oncology

English

PC07.01 Debate 1: Chemotherapy Will Become a Thing of the Past in the Management of Advanced NSCLC - For

Journal of Thoracic Oncology

English

MA15.03 PD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA Trial

Journal of Thoracic Oncology

English

OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated With Anti-Pd-(L)1 Therapy

Journal of Thoracic Oncology

English

P1.16-47 Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report From ALCHEMIST (Alliance A151216)

Journal of Thoracic Oncology

English

P1.01-88 Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFRm-Positive Stage III NSCLC (LAURA)

Journal of Thoracic Oncology

English

P3.12-06 SLFN11 Expression and Efficacy of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study

Journal of Thoracic Oncology

English

MA05.01 E6508: Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Unresectable Stage III NS-NSCLC

Journal of Thoracic Oncology

English

MA18.10 Evolving Immunotherapy Practice Patterns in Advanced NSCLC: Analysis of an Online Treatment Decision Tool

Journal of Thoracic Oncology

English

Better Overall Survival With Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis

International Journal of Radiation Oncology Biology Physics

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Ramalingam

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

PC07.01 Debate 1: Chemotherapy Will Become a Thing of the Past in the Management of Advanced NSCLC - For

MA15.03 PD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA Trial

OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated With Anti-Pd-(L)1 Therapy

P1.16-47 Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report From ALCHEMIST (Alliance A151216)

P1.01-88 Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFRm-Positive Stage III NSCLC (LAURA)

P3.12-06 SLFN11 Expression and Efficacy of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study

MA05.01 E6508: Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Unresectable Stage III NS-NSCLC

MA18.10 Evolving Immunotherapy Practice Patterns in Advanced NSCLC: Analysis of an Online Treatment Decision Tool

Better Overall Survival With Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis